Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 31:12:982461.
doi: 10.3389/fonc.2022.982461. eCollection 2022.

Five-year relative survival by stage of breast and colon cancers in northern Italy

Lucia Mangone  1 , Francesco Marinelli  1 , Isabella Bisceglia  1 , Maria Barbara Braghiroli  1 , Angela Damato  2   3 , Carmine Pinto  2
Affiliations

Five-year relative survival by stage of breast and colon cancers in northern Italy

Lucia Mangone et al. Front Oncol. .

Abstract

The aim of this study is to present the 5-year relative survival by stage of breast and colorectal cancer patients in a northern Italian province. For the period 2013-2015, cases were selected from the Reggio Emilia Cancer Registry. Breast cancer patients were divided into 3 age groups: <45, 45-74 (the target screening population) and 74+. Colorectal cancers patients were classified into <50, 50-69 (the target screening population), and over 69 years. Carcinomas in situ and unknown stage were both excluded from the survival analyses. The five-year relative survival was estimated using the Pohar Perme method. During the period examined, 1,450 breast cancers and 992 colorectal cancer cases were registered. Analyzing in detail the patients with breast cancer for the entire 2013-2015 period, we noted that 50.4% were in stage I, 33.6% in stage II, 10.8% in stage III and 3.8% in stage IV. The stage was unknown in only 1.3% of patients (19 cases). The stage data of patients with colorectal cancer showed 24.5% were in stage I, 26.1% in stage II, 23.4% in stage III, and 24.6% in stage IV, and 1.4% unknown. Breast cancer 5-year survival was 100%, 89.7%, 71.4%, and 29.1% for stages I, II, III and IV, respectively and for colon cancer 96.7%, 83.4%, 70.8% and 16.2%, respectively.The presence of cancer screening, associated with effective treatments, account for the high survival rate of early-stage breast and colon cancers.

Keywords: breast cancer; colorectal cancer; five-year survival; incidence; stage.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Province of Reggio Emilia, 5-year relative survival by stage and site.
Figure 2
Figure 2
Province of Reggio Emilia, incidence and mortality trend (A=breast; B= colon, males; C=colon, females).
See this image and copyright information in PMC

References

    1. I numeri del cancro in Italia 2020 . (2020). AIOM-AIRTUM-SIAPEC-IAP. Intermedia editore.
    1. I numeri del cancro in Italia 2021 . (2021). AIOM-Registri Tumori Italiani-SIAPEC-IAP-Passi-Passi d’Argento. Intermedia editore.
    1. Estève J. Incidence du cancer du sein en France et dans les pays développés [Incidence of breast cancer in France and other industrialized countries. Presse Med (2007) 36(2 Pt 2):315–21. doi: 10.1016/j.lpm.2006.12.007 - DOI - PubMed
    1. Vicentini M, Zorzi M, Bovo E, Mancuso P, Zappa M, Manneschi G, et al. ; colorectal cancer screening IMPATTO study working group. impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study. Int J Cancer (2019) 145(1):110–21. doi: 10.1002/ijc.32089 - DOI - PubMed
    1. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol (2020) 21(4):519–30. doi: 10.1016/S1470-2045(19)30863-0 - DOI - PubMed

LinkOut - more resources